ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Expanding on an earlier pact, AbbVie will pay Harpoon Therapeutics $50 million for an option to license HPN217, a bispecific antibody that targets B-cell maturation antigen, and to add six targets to the firms’ existing discovery deal. Harpoon could get another $50 million when the first person is treated with HPN217 in the clinic. AbbVie will decide whether to buy global rights to the drug after a planned Phase I/II study in multiple myeloma is completed.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter